Padeliporfin potassium by ImPact Biotech for Esophageal Cancer: Likelihood of Approval

Padeliporfin potassium is under clinical development by ImPact Biotech and currently in Phase I for Esophageal Cancer.

Traditional Chinese medicine shows potential in cancer treatment

Cancer, a pervasive global health concern, remains a leading cause of mortality worldwide. Current cancer treatment modalities encompass surgery, radiotherapy, chemotherapy, immunotherapy, and targeted therapy,

October 1, 2024

NCCN publishes new resource on options, benefits of care approaches for pediatric Hodgkin lymphoma

The National Comprehensive Cancer Network today announced the publication of NCCN Guidelines for Patients®: Hodgkin Lymphoma in Children.

August 23, 2023

New zwitterionic polyion developed for effective plasmid DNA delivery in muscle cells

Researchers from Tokyo Metropolitan University have created a new drug delivering molecule, a zwitterionic polymer complex that can help get plasmid DNA inside cells when

July 29, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.